Thomas Dedenroth Miller

Title: Innovations of Thomas Dedenroth Miller in Diabetes Treatment

Introduction

Thomas Dedenroth Miller, an inventive mind based in Seattle, WA, has made significant contributions to the field of diabetes treatment. With an impressive portfolio of 12 patents, his work focuses on enhancing insulin administration through innovative technologies and methodologies.

Latest Patents

Two of Miller's most recent patents showcase his expertise in insulin delivery systems. The first patent introduces an insulin titration algorithm based on patient profiles. This device, system, and method predict the risk of hypoglycemia and adjust the insulin medicament dose size for subjects using pen-based multi-daily injections. His algorithm computes a first insulin dose size based on timestamped blood glucose (BG) measurements and previously injected doses. The risk prediction module leverages machine learning to forecast the hypoglycemia risk, calculating a second insulin dose size to ensure a non-hypoglycemic state. If the second dose is lower than the first, the recommended dose size is automatically adjusted.

The second patent focuses on providing up-to-date guidance on long-acting or ultra-long-acting insulin doses for treating diabetes mellitus. The invention outlines a novel regimen for insulin administration, collecting multiple data sets and structures to create customized dose guidance recommendations. This innovation aims to improve the management of conditions where insulin administration is beneficial, thus enhancing patient outcomes.

Career Highlights

Miller's career is marked by his affiliation with Novo Nordisk A/S, a global healthcare company dedicated to diabetes care and other chronic conditions. His work involves the development of advanced technological solutions that directly impact patient care in the diabetes sector.

Collaborations

Throughout his career, Miller has collaborated with talented colleagues such as Steffen Hansen and Brad Warren Van Orden. Together, they have contributed to the advancement of diabetes treatment through their combined expertise and innovative efforts at Novo Nordisk A/S.

Conclusion

Thomas Dedenroth Miller's innovations in insulin delivery and management systems exemplify the critical role of inventors in addressing complex health issues like diabetes. His continued work at Novo Nordisk A/S reflects a commitment to improving treatment outcomes for patients, showcasing the importance of innovative thinking in the field of medical technology.